Royce & Associates’s Correvio Pharma Corp. Ordinary Shares (Canada) CORV Stock Holding History

Royce & Associates’s Portfolio CORV Stock Details CORV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-101,100	Closed	-$41K	–	1214
2019 Q4	$41K	Sell	101,100 -1,312,375	-93%	-$2.18M	﹤0.01%	1060
2019 Q3	$2.83M	Buy	1,413,475 +785,475	+125%	+$1.59M	0.03%	628
2019 Q2	$1.36M	Buy	628,000 +145,500	+30%	+$372K	0.01%	798
2019 Q1	$1.52M	Hold	482,500	–	–	0.01%	800
2018 Q4	$1.2M	Buy	482,500 +227,600	+89%	+$758K	0.01%	834
2018 Q3	$1.02M	Buy	+254,900	New	+$1.12M	0.01%	914

Other funds holding CORV

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Royce & Associates's CORV Position: Q1 2020 in Review

Royce & Associates sold out of Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) in Q1 2020, closing a stake of 101,100 shares — an estimated $41K sold.

Royce & Associates first reported a position in CORV in Q3 2018 and held it in 6 quarters. The position peaked at $2.83M in Q3 2019. 27 funds tracked by Wall St. Rank hold CORV as of Q1 2020.

Royce & Associates reported no remaining Correvio Pharma Corp. Ordinary Shares (Canada) position as of Q1 2020 after selling out during the quarter.
Royce & Associates sold 101,100 Correvio Pharma Corp. Ordinary Shares (Canada) shares in Q1 2020, an estimated $41K.
Royce & Associates first reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) in Q3 2018 and held it in 6 quarters.
Royce & Associates's Correvio Pharma Corp. Ordinary Shares (Canada) position peaked at $2.83M in Q3 2019.
27 funds tracked by Wall St. Rank held Correvio Pharma Corp. Ordinary Shares (Canada) as of Q1 2020.

Based on Royce & Associates's 13F filing for Q1 2020, filed 12 May 2020.